AKBA
Price
$1.37
Change
+$0.07 (+5.38%)
Updated
May 3, 6:59 PM EST
One day until earnings call
PHAT
Price
$10.04
Change
+$0.28 (+2.87%)
Updated
May 3, 6:59 PM EST
4 days until earnings call
Ad is loading...

Compare trend and price AKBA vs PHAT

Header iconAKBA vs PHAT Comparison
Open Charts AKBA vs PHATBanner chart's image
Akebia Therapeutics
Price$1.37
Change+$0.07 (+5.38%)
Volume$1.83M
CapitalizationN/A
Phathom Pharmaceuticals
Price$10.04
Change+$0.28 (+2.87%)
Volume$362.59K
CapitalizationN/A
View a ticker or compare two or three
AKBA vs PHAT Comparison Chart

Loading...

AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PHATDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AKBA vs. PHAT commentary
May 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Hold and PHAT is a Hold.

COMPARISON
Comparison
May 05, 2024
Stock price -- (AKBA: $1.37 vs. PHAT: $10.04)
Brand notoriety: AKBA and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 53% vs. PHAT: 82%
Market capitalization -- AKBA: $287.15M vs. PHAT: $587.58M
AKBA [@Biotechnology] is valued at $287.15M. PHAT’s [@Biotechnology] market capitalization is $587.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $545.88B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whilePHAT’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • PHAT’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKBA and PHAT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 6 TA indicator(s) are bullish while PHAT’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 6 bullish, 4 bearish.
  • PHAT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AKBA is a better buy in the short-term than PHAT.

Price Growth

AKBA (@Biotechnology) experienced а +2.24% price change this week, while PHAT (@Biotechnology) price change was +9.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -3.94%, and the average quarterly price growth was +1240.85%.

Reported Earning Dates

AKBA is expected to report earnings on Aug 01, 2024.

PHAT is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AKBA with price predictions.
OPEN
A.I.dvisor published
a Summary for PHAT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
PHAT($588M) has a higher market cap than AKBA($287M). AKBA YTD gains are higher at: 10.484 vs. PHAT (9.967).
AKBAPHATAKBA / PHAT
Capitalization287M588M49%
EBITDAN/AN/A-
Gain YTD10.4849.967105%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAPHAT
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 17 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Ad is loading...
AKBADaily Signal changed days agoGain/Loss if shorted
 
Show more...
PHATDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEDCX33.110.40
+1.22%
Invesco EQV European Equity C
PSOPX27.640.30
+1.10%
JPMorgan Small Cap Value I
BGRKX9.010.09
+1.01%
BlackRock Global Equity Abs Rtn K
VGIFX79.220.41
+0.52%
JPMorgan US Value R5
RAGHX29.540.08
+0.27%
Virtus KAR Health Sciences A

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with AVIR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+5.38%
AVIR - AKBA
34%
Loosely correlated
+3.39%
VCYT - AKBA
33%
Poorly correlated
+0.79%
CRSP - AKBA
31%
Poorly correlated
+1.49%
PRME - AKBA
31%
Poorly correlated
-0.36%
KNSA - AKBA
31%
Poorly correlated
+3.61%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with VERA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then VERA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+2.87%
VERA - PHAT
43%
Loosely correlated
-0.14%
ATRA - PHAT
36%
Loosely correlated
+3.03%
OCGN - PHAT
35%
Loosely correlated
+0.76%
ATNM - PHAT
35%
Loosely correlated
+2.40%
ZNTL - PHAT
32%
Poorly correlated
+5.40%
More